160 related articles for article (PubMed ID: 18483317)
1. PBISe, a novel selenium-containing drug for the treatment of malignant melanoma.
Madhunapantula SV; Desai D; Sharma A; Huh SJ; Amin S; Robertson GP
Mol Cancer Ther; 2008 May; 7(5):1297-308. PubMed ID: 18483317
[TBL] [Abstract][Full Text] [Related]
2. Melanoma prevention using topical PBISe.
Chung CY; Madhunapantula SV; Desai D; Amin S; Robertson GP
Cancer Prev Res (Phila); 2011 Jun; 4(6):935-48. PubMed ID: 21367959
[TBL] [Abstract][Full Text] [Related]
3. The selenium analog of the chemopreventive compound S,S'-(1,4-phenylenebis[1,2-ethanediyl])bisisothiourea is a remarkable inducer of apoptosis and inhibitor of cell growth in human non-small cell lung cancer.
Das A; Bortner J; Desai D; Amin S; El-Bayoumy K
Chem Biol Interact; 2009 Jul; 180(2):158-64. PubMed ID: 19497413
[TBL] [Abstract][Full Text] [Related]
4. Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats.
Janakiram NB; Mohammed A; Ravillah D; Choi CI; Zhang Y; Desai D; Amin S; Rao CV
Oncol Rep; 2013 Aug; 30(2):952-60. PubMed ID: 23708609
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of a novel iNOS/Akt inhibitor Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe)--against colon cancer.
Desai D; Madhunapantula SV; Gowdahalli K; Sharma A; Chandagaludoreswamy R; El-Bayoumy K; Robertson GP; Amin S
Bioorg Med Chem Lett; 2010 Mar; 20(6):2038-43. PubMed ID: 20153642
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.
Gowda R; Madhunapantula SV; Desai D; Amin S; Robertson GP
Mol Cancer Ther; 2013 Jan; 12(1):3-15. PubMed ID: 23112250
[TBL] [Abstract][Full Text] [Related]
7. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates.
Sharma A; Sharma AK; Madhunapantula SV; Desai D; Huh SJ; Mosca P; Amin S; Robertson GP
Clin Cancer Res; 2009 Mar; 15(5):1674-85. PubMed ID: 19208796
[TBL] [Abstract][Full Text] [Related]
8. A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer.
Tagaram HR; Desai D; Li G; Liu D; Rountree CB; Gowda K; Berg A; Amin S; Staveley-O'Carroll KF; Kimchi ET
Pharmaceuticals (Basel); 2016 Mar; 9(2):. PubMed ID: 27023566
[TBL] [Abstract][Full Text] [Related]
9. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
[TBL] [Abstract][Full Text] [Related]
10. Selenium-containing histone deacetylase inhibitors for melanoma management.
Gowda R; Madhunapantula SV; Desai D; Amin S; Robertson GP
Cancer Biol Ther; 2012 Jul; 13(9):756-65. PubMed ID: 22669577
[TBL] [Abstract][Full Text] [Related]
11. Chemopreventive effects of a selective nitric oxide synthase inhibitor on carcinogen-induced rat esophageal tumorigenesis.
Chen T; Nines RG; Peschke SM; Kresty LA; Stoner GD
Cancer Res; 2004 May; 64(10):3714-7. PubMed ID: 15150132
[TBL] [Abstract][Full Text] [Related]
12. PRAS40 deregulates apoptosis in malignant melanoma.
Madhunapantula SV; Sharma A; Robertson GP
Cancer Res; 2007 Apr; 67(8):3626-36. PubMed ID: 17440074
[TBL] [Abstract][Full Text] [Related]
13. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells.
Jiang C; Wang Z; Ganther H; Lü J
Mol Cancer Ther; 2002 Oct; 1(12):1059-66. PubMed ID: 12481429
[TBL] [Abstract][Full Text] [Related]
14. Novel seleno- and thio-urea derivatives with potent in vitro activities against several cancer cell lines.
Alcolea V; Plano D; Karelia DN; Palop JA; Amin S; Sanmartín C; Sharma AK
Eur J Med Chem; 2016 May; 113():134-44. PubMed ID: 26922233
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor.
Rao CV; Kawamori T; Hamid R; Reddy BS
Carcinogenesis; 1999 Apr; 20(4):641-4. PubMed ID: 10223193
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative activity of vanadium compounds: effects on the major malignant melanoma molecular pathways.
Pisano M; Arru C; Serra M; Galleri G; Sanna D; Garribba E; Palmieri G; Rozzo C
Metallomics; 2019 Oct; 11(10):1687-1699. PubMed ID: 31490510
[TBL] [Abstract][Full Text] [Related]
17. Searching for the Achilles' heel of melanoma cells: new treatment modalities.
Melnikova VO; Bar-Eli M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):505-6. PubMed ID: 18713130
[No Abstract] [Full Text] [Related]
18. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation.
Albino AP; Juan G; Traganos F; Reinhart L; Connolly J; Rose DP; Darzynkiewicz Z
Cancer Res; 2000 Aug; 60(15):4139-45. PubMed ID: 10945621
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
20. Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.
Kuzu OF; Gowda R; Sharma A; Noory MA; Kardos G; Madhunapantula SV; Drabick JJ; Robertson GP
Cancer Biol Ther; 2018 Jan; 19(1):53-62. PubMed ID: 28853983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
